# DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

> **NCT03265717** · PHASE2 · TERMINATED · sponsor: **Invectys** · enrollment: 26 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **BIOLOGICAL:** INVAC-1

## Key facts

- **NCT ID:** NCT03265717
- **Lead sponsor:** Invectys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-25
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2020-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03265717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03265717, "DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03265717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*